Author Topic: (Abst.) Progression rates, sample size estimates for PPMS...  (Read 88 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Progression rates, sample size estimates for PPMS...
« on: February 15, 2015, 03:56:35 pm »
From Multiple Sclerosis Journal, February 13, 2015:

Quote
Progression rates and sample size estimates for PPMS based on the CLIMB study population

Kesav Raghavan
Partners Multiple Sclerosis Center, Brigham and Women’s Hospital, USA

Brian C Healy
Partners Multiple Sclerosis Center, Brigham and Women’s Hospital, USA/Biostatistics Center, Massachusetts General Hospital, USA

Robert L Carruthers
Partners Multiple Sclerosis Center, Brigham and Women’s Hospital, USA

Tanuja Chitnis
Partners Multiple Sclerosis Center, Brigham and Women’s Hospital, USA

Partners MS Center, Brigham and Women’s Hospital, 1 Brookline Place, Suite 602, Brookline, MA 02445, USA. tchitnis@partners.org

Background:

The clinical trial design for primary progressive multiple sclerosis (PPMS) requires understanding of disability progression in modern patient cohorts.

Objective:

The objective of this paper is to characterize demographic and clinical characteristics of PPMS and assess rate of disability progression.

Methods:

We studied PPMS (n = 73) and relapsing-onset MS (ROMS) patients (n = 1541) enrolled in CLIMB, a longitudinal study of MS patients at the Brigham and Women’s Hospital (Boston, MA). Disability progression for each group was compared using interval-censored survival analysis and time to six-month sustained progression.

Results:

The PP group had a 1.09:1 male:female ratio compared to 1:2.89 for the RO group and greater mean age of onset (PP: 44.4±9.6; RO: 32.7±9.9; p < 0.0001). Motor symptoms at onset and first symptoms localized to spinal cord were each strongly associated with PPMS (p < 0.001). Median time from onset to EDSS 6.0 was faster in PPMS (p < 0.001). PPMS patients progressed faster to EDSS 3 (p < 0.001) and from EDSS 3 to 6 (p < 0.001). Median time to sustained progression in the PP group was 4.85 years (95% CI 2.83–8.35), significantly faster than the RO group (p < 0.001).

Conclusions:

Our modern PPMS cohort is demographically similar to previously studied cohorts. PPMS is associated with faster disability accrual than ROMS. Current real-world observations of time to sustained progression will inform design of new clinical trials for PPMS.
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.